Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 12/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758488 | 0.89 | GABRG2 (0.43) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL6508596 | 0.85 | NR1H2 (0.39) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL10553045 | 0.84 | NR1H2 (0.39) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL10552835 | 0.83 | NR1H2 (0.40) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL18848182 | 0.82 | NR1H2 (0.40) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL4037148 | 0.82 | CYP2A6 (0.38) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL18437161 | 0.82 | NR1H2 (0.37) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL20888261 | 0.81 | GABRG2 (0.42) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL27108521 | 0.81 | NR1H2 (0.46) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL17422843 | 0.80 | NR1H2 (0.56) | NR1H2NR1H3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | GABRG2 1780/4885GABRB3 936/4885GABRA5 1312/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | GABRG2 1621/4885GABRB3 775/4885GABRA5 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.